Data di Pubblicazione:
2015
Citazione:
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes / Cannon, C.p., Blazing, M.a., Giugliano, R.p., Mccagg, A., White, J.a., Theroux, P., Darius, H., Lewis, B.s., Ophuis, T.o., Jukema, J.w., De Ferrari, G.m., Ruzyllo, W., De Lucca, P., Im, K., Bohula, E.a., Reist, C., Wiviott, S.d., Tershakovec, A.m., Musliner, T.a., Braunwald, E., et al.. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 372:25(2015), pp. 2387-97-2397. [10.1056/NEJMoa1410489]
Abstract:
Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Simvastatin; Triglycerides
Elenco autori:
Cannon, Cp; Blazing, Ma; Giugliano, Rp; Mccagg, A; White, Ja; Theroux, P; Darius, H; Lewis, Bs; Ophuis, To; Jukema, Jw; De Ferrari, Gm; Ruzyllo, W; De Lucca, P; Im, K; Bohula, Ea; Reist, C; Wiviott, Sd; Tershakovec, Am; Musliner, Ta; Braunwald, E; Califf, Rm; for the IMPROVE-IT, Investigators; Cianflone, D
Link alla scheda completa:
Pubblicato in: